Welcome to Good Medicine, a podcast about the ideas, people, and conversations shaping the future of healthcare. I'm your host, Dr. Rohan Ramakrishna, neurosurgeon and co-founder of Rune. Each episode, we explore how medicine is evolving through honest conversations with leaders and changemakers. Good Medicine is brought to you by Rune, the digital home for doctors. We're a free physician-led community to connect, share knowledge, and shape the future of medicine.
Mark Cuban is one of the most recognizable faces in American business, but recently he has taken on perhaps his biggest opponent yet: the US healthcare system. He is the founder of the Mark Cuban Cost Plus Drug Company, a public benefit corporation dedicated to radically lowering the price of prescription drugs. In this episode, we trace Mark's journey from his very first hustle at age 12, selling garbage bags door to door to buy basketball shoes, to his current mission to dismantle the opaque pricing models of the pharmaceutical industry. We discuss the origin story of Cost Plus Drugs, why he believes hospitals have been forced into the role of subprime lenders, and his strategic advice for how doctors and hospitals can break free from the administrative burden of big insurance.
A few things from our conversation really stuck with me. First, Mark completely flips the standard career advice on its head. He argues you shouldn't just follow your passion, but rather follow your effort. It's a pragmatic look at how curiosity and the willingness to learn, even if it's just reading the manual at a software store, can lead to unexpected success. Second, he breaks down his formula for trust. Mark explains that trust equals transparency divided by self-interest. This is the governing philosophy behind his 15% markup model. He argues that the healthcare industry has eroded trust through opacity, and the only way to win it back is by showing your mouth. Third, we go deep into the mishagas, to use Mark's word, of pharmacy benefit managers, or PBMs. Mark gives a crash course on the flow of money in the drug supply chain, exposing exactly how rebates and intermediaries inflate costs for patients while squeezing providers. He also shares a fascinating vision for the future of manufacturing, where hospitals could use robotic pods in their parking lots to manufacture sterile injectables and personalized gene therapies on site. In this interview, Mark brings his trademark intensity, business savvy, and showcases a genuine desire to let doctors get back to the business of doctoring. Join us for the conversation.
So, we are living through tumultuous times in healthcare. As we speak, the government is shut down. SNAP benefits for millions of Americans are due to expire, and the healthcare subsidies that Americans depend on for affordable healthcare insurance are lapsing, leading to a massive spike in people's healthcare insurance premiums. But thankfully, there are folks out there who are trying to make things better. And so today, I'm so happy to be joined by entrepreneur, investor, Shark Tank host, Dallas Mavericks owner, and now healthcare reformer Mark Cuban. So Mark, welcome to Good Medicine.
So Mark, I want to start with a little bit of your time before the Mavs, before Broadcast.com, etc., and really walk through the very beginning. Walk me through your first hustle. You know, when did you, how old were you? What did you do? And what did that experience teach you?
Nine, 10 years old. I grew up in Pittsburgh, Pennsylvania, middle-class neighborhood, and I would buy packages of baseball cards. And since we were all Pittsburgh Pirates fans, I would repackage them. So every, you know, every few packages would have a Pirates player in it, and I could sell them at a premium and make some money and fill my habit by going up and buying other cards, etc., etc. So that was the first time. And then when I was 12 years old is where it really kicked off.
I wanted a new pair of basketball shoes. I've been a basketball junkie as long as I can remember. My dad had a bunch of his buddies playing poker at the house, and I'm sure they were just lit. And anyways, I walked in there to just say hi and get a donut or whatever. And I asked my dad if I could get a new pair of basketball shoes, new Converse or whatever, a pair of Bullets, whatever the hot shoes were at the time. And he looked at me and he goes, 'You see those shoes on your feet? They will look just fine. When you have a job, you can buy whatever you want. Until then, those shoes will do the trick.' I'm like, 'Dad, I'm 12. How am I going to get a job?' And one of his buddies at the poker table was like, 'I got something for you. I've got these boxes of garbage bags that you can go door to door in the neighborhood and sell.' And I was like, 'Cool. Can I do it, Dad?' He was like, 'Sure.'
And so that really was the beginning. I mean, you can imagine it, walking up to a neighbor and going, 'Hi, my name is Mark. Do you use garbage bags?' And that's just what set me off, you know. And once I learned how to sell, that gave me confidence to do anything.
Well, that's very cool. So fast forward a bit, you started Broadcast.com, right? And what was the origin story there? Were you trying to solve a personal problem for yourself in terms of watching Indiana?
Yeah. So Indiana, up until last year and this year, was a huge basketball school. Now it's as much a football school as anything. And to listen to our big basketball games in Dallas, Texas, you know, before 1995, we would literally get somebody in Bloomington, Indiana, to put a speakerphone next to a radio. We would have a speakerphone down in Dallas and a 12-pack of beer or whatever, and we'd sit there and yuck it up and listen to the games if it wasn't on television on national TV. We just had to follow it, you know, in the beginnings of the internet with online services like America Online and CompuServe, etc. So I was like, there's got to be a better way. I had sold my first company, MicroSolutions, a few years earlier, and we did systems integration. And I wrote software, connected PCs in the local and wide area networks, so I had a general feel. And so we started a company, my buddy and I, Todd Wagner, started a company called AudioNet, where the goal was to be able to stream — we called it netcasting or internet broadcasting at the time — but to send audio anywhere over the internet. And that's how the whole internet streaming industry started.
That's very cool. So, you know, listening through all of this, you know, you clearly follow your passions, right? And I think that's advice that often mentors give.
And actually, I'm not a follow-your-passion type guy at all. I'm not a believer in the whole follow your passion. I'm a big believer in follow your effort.
You know, where do you put your time? Because my passion was to be a baseball or basketball player. My reality was, you know, it wasn't going to happen. And so, even though I thought I was good at the time, but what I found myself really excited about by that point in time was technology. And I didn't even take technology in school. I got a job at a software store and it was basically teach myself everything to learn until I got fired, which is a whole other story. But in any event, that led me to starting MicroSolutions. But I just realized that I had an aptitude for it. And I've always been curious. I always love to learn to this minute. You know, I'm as curious as anybody you'll ever meet to just keep on learning. And that's always served me well. And so I've, you know, when people have always said, well, follow your passions, I've never been a big believer in that. It's like follow the things you like to learn.
And the things you like to learn may not coincide with what you're passionate about, you dream about, you know, that tennis career, that music career, being a hip-hop artist, a rock star. But if you find yourself, like in my case, loving to learn about technology and loving to learn about business, that's the path you typically will take because that's where you follow your efforts.
Yeah. And what I was going to say also is, in addition, you know, people give that advice about following your passions, but so much of it is also where do your set of unique skills and expertise line up, you know, to support that.
And the only way to find out is to try different things, right? If you would ask me when I was 18 years old, you know, would I be in technology, I would have laughed at you. You know, I would have been like, no, I just want to start my own business. I'm not, you know, I'm not into computers until I tried it because I'd never really done much with it, you know. And so, you know, you've got to go out there. And I tell kids today, you know, the job market, AI, there's a lot of uncertainty, but I tell them, you spent four years paying to go to, paying to learn. The minute you graduate, you have the opportunity to get paid to learn. Whatever that job may be, it doesn't need to be the perfect job. It doesn't need to be a career. Particularly now, you know, back in the day, you used to look at a resume and say, 'Oh, you were only there two years.' You know, you jump around to jobs. Now, people expect that. And you know, you're like an NBA free agent every season. And so by going to different jobs, you're getting paid to learn and you get to find out more about yourself and how business works, how companies work, how, you know, what it's like to be responsible. And so I think you don't, you know, when you're young in particular, you don't have to have it all figured out. You want to go out and experience all these different things.
And now with AI, oh my god, you know, every AI model out, you know, frontier model out there is like having every med school library, having every business school library, every consultant, etc., etc., available to you at your fingertips. So a 12-year-old, 16-year-old, 22-year-old, 88-year-old, you know, if you're willing to say to ChatGPT, Perplexity, you know, Gemini, any of them, 'Hey, I want to learn Polish because I have this business deal,' or 'Help me put together a business plan for this idea.' You know, back in the day, we would have sat on the internet for 12 hours going through all these links trying to accumulate it all together and we still might not get it right. And now, you know, an AI model might not give you a perfect answer, but nobody, no professor, nobody ever can give you a perfect answer, but it'll save you a lot of time and save you, you know, and give you a head start and an opportunity to democratize your entrance into being an entrepreneur or whatever industry.
Right. Well, with that, I wanted to get into healthcare. And so, you know, so tell me what, you know, it's not obvious that this is a place you would land at this sort of stage of your career. So I'm curious, what got you into healthcare?
Well, I mean, I'm just getting started in my career, so I mean, I figured I'd try new things. And so, well, going back to like 2017 when the Republicans started talking about overturning the ACA, being in Texas, I got a lot of questions, you know, 'What would you do? What would you do?' And so I started digging into it some and looking at different payment models and the like. And then 2019, maybe 2020, I got a cold email from a Dr. Alex Oshmyansky, who was a radiologist and probably the smartest person I know, you know, one of these math scholars who, you know, takes on math problems just for fun, you know, and he goes to conferences to learn math, you know, how to solve this theorem, I don't even know. So anyways, he sends me a cold email and he says, 'I want to create a compounding pharmacy that makes drugs that are in short supply, in particular sterile injectables.' I'm like, 'That's interesting. What the hell is all that?' So he starts explaining that to me. And at the same time, this is when the pharma bro was going to jail, and I was like, 'How can this one dude jack up the price of this generic drug, Daraprim, 7,500% or whatever it was, and get away with it?' And he started explaining things. So that's when I really started digging in and researching everything, and it became obvious that the entire healthcare industry, starting with pharmacy, is completely opaque. And it was opaque for a reason. I might not have understood what all the drugs could do and what they all meant, but I understood how business works. And I understood when, you know, the more opacity there is, the less knowledge, the more unbalanced the negotiation is. And so I saw an opportunity and we created costplusdrugs.com with a simple goal, right? To be completely transparent. And how did we do that? We made it so that when you go to costplusdrugs.com, then like now you put in the name of medication, if it's one of the thousands we carry — we don't have them all, but we have a lot — it comes up and it shows you our actual cost. Then it shows you our markup, which is 15%. Then it shows you, because if it's mail order, it's $5 for a pharmacist to look at it, $5 for shipping, and that's our total cost. And because we did it that way and we had a fair markup, we were less expensive, particularly on more expensive drugs, than anybody else. And that led to us going from 111 drugs on January 19th of 2022 when we launched to thousands more now. And as our volumes have gone up, you know, our prices have gone down. And when our costs go down, we pass them along. And that's led to us making millions of people happy.
That's awesome. Where did the 15% come from? Out of curiosity, was there a reason you picked that?
Yeah. Just out of thin air because I thought it was fair.
You know, and since then — I didn't know it at the time, but since then I listened to a podcast and I think it was a doctor that said something that really resonated with me. He said, 'Trust can be defined as a formula.' Trust equals transparency as the numerator divided by self-interest as the denominator. So the higher, the more transparent you are, the higher the numerator. And the less self-interest you have, the lower the denominator. And so by having a 15% markup, people realized that our self-interest wasn't, you know, overwhelming. We weren't trying to sell at market price. We were selling at a fair price that is going to be less than market. And that's really worked out for us because, as I would tell, you know, we hired people who came from the healthcare industry in the pharmacy business, and they initially were trying to do things the way it was done in the industry. And I just had to remove all of those instincts from them and remind them that we don't really sell drugs. That's not our product. Our product is trust. Because in the healthcare industry across the board, including pharmacy, people trust their doctors, people trust their pharmacist, but they trust nothing about the economics or finances of healthcare. And since that was our differentiator, we had to make sure that people trusted us, and that truly was our product.
Using that formula, there's certain organizations that could have trust scores near infinity, right? Potentially. But where would you, how would you rank Cost Plus on that formula? How would you rank hospitals, doctors, payers, providers, you know?
Yeah, that's a broad question, right? Obviously, you know, we're completely transparent. I mean, we're not allowed to show some of the contracts we have with some companies. So that's, I guess, we're not completely transparent. And we've tried to get our manufacturers to do that, but because of PBMs, they're afraid to do it. But beyond that, I think we're very transparent. But the nature of the economics of the healthcare industry, starting on the medical side, which includes the pharmacy benefits, is so convoluted, it creates problems. And it creates problems for doctors. You guys are underpaid as a result. You guys are overworked as a result. And I'll go through it. It starts with an insurance plan.
If you think about what happens with an insurance plan from the big carriers, right, that you guys are way too familiar with. Doctors shouldn't have to understand the insurance industry, but yet you do. But it starts with there's a trade-off between how high a premium is and how low the deductible is, right? It's an inverse relationship. And then the people choosing a plan, whether it's your employer, a state employer, or ACA now going through open enrollment, you know, the people who have the biggest financial problems typically tend to get lower premiums and higher deductibles and hope they don't get sick. Well, that's the first fundamental problem of the healthcare industry because there's no credit check, right? And I'm not saying there should be, but you know, in a country where 40% of people can't afford $400 if there's an emergency, well, by definition, if you have an ACA plan which is about to go up to a $5,000 deductible and you can't afford $400 and you're not on Medicaid, you're stuck if something happens.
Yeah. Basically, what you're referring — what I think you're also pointing out is that so many of our citizens in this country are effectively uninsured even if they do have insurance.
Oh, yeah. For sure. Yeah, healthcare is not a proxy — I mean, health insurance is not a proxy for healthcare, right?
And that starts to create the problem. Anybody, you know, the average corporate deductible is in the 1,500 to 2,000 range, right? The ACA is higher than 4,500, and the max out-of-pockets are like 5,000 to 10,000 per corporate, and now going up to 20,000 plus for a family of five for an ACA plan. And so that is a real problem most people cannot afford. But that leads to the overall construction of the economics in healthcare problem because who takes on the credit risk if a patient can't pay their deductible?
Yeah. Hospitals do, right? So now we've turned hospitals into subprime lenders for — we don't even know the total amount, but we know there are, you know, hundreds of billions of dollars in unpaid medical debt, right? And so that's almost as big as the subprime lending crisis in real estate in the Great Recession, right? So now you've got these hospitals who have to, and providers, practices that have to take on this debt, right, from patients because they're not going to just say you're out of luck, right? And they want them to be able to reach their deductible so then they can hopefully get paid by the insurance company. So they'll loan them money or they'll use a third party to loan them money.
And that creates obviously a challenge because if they try to collect it, they're the bad guys, but then if they don't, they lose the money.
And so depending on the hospital and where you're located, you could see 50% write-offs. So put that in one bucket of providers having to subsidize patients, right? Then you look at the contracts that they sign with the BUAs, right? So you want to be part of a network. First, with that contract, there's a ton of overhead associated with it, right? You've got to have the people to process it. You've got to be able to look for the copay, the coinsurance, all those things. That's expensive. And they come up with new plans every year, and everybody gets a new card and chooses a new plan every year, which makes it even more expensive. But to make matters worse, first of all, those big BUAs negotiate higher prices than any Joe Schmo walking in off the street with a credit card, right? Because the hospitals know there's all kinds of associated costs with it.
And so, but not only is it a higher negotiated rate, but they don't even pay the full amount. So if they negotiate a rate, like a $25,000 rate for a hip replacement, they might say, 'We'll pay you 20, right?' And now the hospital is out — I'm talking to hospital CFOs — they're out another 3 to 5%. So they're a subprime lender writing off debt. They're out another 3 to 5%. And then there's your favorite prior authorizations, where the insurance company has a 97-year-old veterinarian trying to make a determination on oncology, right? And their goal really isn't to deny coverage most of the time. Their goal is just to delay coverage because — or the procedure — because they get the time value of money and the hospital loses that time value of money. And on top of that, you've probably spent way too many hours talking to that veterinarian who runs that committee, right? How many hours a week do you spend dealing with pre-auth committee discussions?
Well, we have to hire teams of people. It's impossible for even one person to do it, right? I'm a surgeon.
Now, your costs go up even more. So now we go back to the original question, right? Why is it that we are where we are and who is trustworthy in the entire economic side of all this? Well, the insurance companies, no. The PBMs, no. Now, what about the hospitals? Maybe, right? Because now the hospitals are at a disadvantage because they have all these expenses associated with doing what they pretty much have to do to get patient flow. And so what do they do to compensate? They create dumbass like facilities fees, right? Why facilities fees are relatively new, you know, over the last five years. I don't know the exact date, but you didn't have them 10 years ago, but now everybody does as a way to kind of balance, right? And then on top of that, you've got all the overhead we talked about and all the people that jacks up costs even further. And because of all those costs associated with commercial plans and ACA plans, those same hospitals can't afford, or at least pretend that they can't afford, to take on Medicare and Medicaid patients because of their book of business.
If you took out all that overhead associated with dealing with the BUAs, not only could you charge less, but you would be able to afford dealing with Medicare and Medicaid and hospitals that are focused on that book of business. And that's a term I learned from hospitals: book of business, right? And product mix, right? Yeah. They'd be able — they'd make money at Medicare and Medicaid. Like Duke Health makes a ton of money. They make 4%. Because they're focused on that, and Medicare and Medicaid doesn't have the paperwork obligations that all these commercial insurers have. And so when you pull all these things together, that's how we get a messed-up healthcare system on the economic side. That's why they dig in and they push you guys to have to do nine operations a day to try to hit your RVU numbers, right? I want my doctors rested. I want you guys back to playing golf on Wednesdays, right? No appointment on Wednesdays. Go play golf. I don't want you having in the back of your mind thinking about the complicated tumor extraction that you have to do that's three operations down because you think this is — you've done this enough time and you've got enough help here, right? Not that any doctor is not going to stay completely focused, but everybody's human, right? Yeah. And that just puts so much more pressure on you guys that shouldn't be there. So you're underpaid and overworked and dealing with all kinds of mishagas nonsense that shouldn't be there simply because the starting point is we have deductibles that people can't afford.
Yeah, absolutely. And by the way, you used one of my favorite words, which is mishagas. So, mishagos. Yeah. Hey, what can I say? Now, you've been actually tackling this yourself, which is with direct contracting. Can you talk about that?
Yeah. So what's the solution? A business decision. You want to just — business decision. So the question becomes, knowing all of this, I tried to put myself in the shoes of the hospital, any doctor, provider, right? What's best for them? And given what I just told you, not having to deal with all the mishagos and the contractual and the administration and overhead and all that, and not having to take on the payment risk of the deductible, we created a company called Cost Plus Wellness that isn't a company. It's more of a service that's a free service where for my employees and our members, right? We're going to hospital systems, physicians, practices, clinics, and we're saying, 'Look,' I give them the discussion that you and I just had, and they're on the other side of it, right? So they understand it personally. And I said, 'There won't be any pre-authorizations. By the time a patient gets to you, we've already approved it and gone through everything. Whatever we negotiate is what we pay, and we pay you right away. Cash, straight-up money. And so we want you to treat us like a cash-pay customer. And for the things that you don't list with a cash-pay price, we want it to be a reference price to Medicare. So it might be 120% of Medicare. If it's a service like an MRI, it might be 80% of Medicare. But if it's something more complicated where it's inpatient, you know, tumor operation and you don't know, there's not a simple exact price, then, you know, we'll negotiate, but we're not exclusive to you. So if there's three hospital systems in a market, you know, and we think the doctor's good and the patient approves of the doctor, then we'll look for the least expensive, high-quality option. But by doing that, we think we can see our healthcare costs on the medical side go down and see our pharmacy bills go down. And for my direct employees, for Mark Cuban companies, we have no out-of-pocket. If you work with one of our Cost Plus Wellness doctors — and there's 9,000 of them and growing now — and if you buy using Cost Plus Drugs, there's no out-of-pocket for you as well or your family because we're saving and we're still seeing our savings increase by going down this path. Now, the challenge is getting everybody to work with us because the key to what we're doing in all this with our direct contracting is on costpluswellness.com by the end of the year, we're going to publish all of our contracts so that any employer can come in and say, 'Wow, I can get a better price,' or 'Mark, your price is too high. We'll beat your price and here's the contract. Will you publish it?' And then it just becomes a more efficient market so that everybody hopefully is happy and the cost of care goes down for everybody.
So as you've kind of done this work with direct contracting with your own businesses and your kind of knowledge and connections now within the healthcare industry, how would you advise hospitals to structure their contracts? What are they doing that they shouldn't, what aren't they doing that they should be doing?
So that's a great question because it really depends on your market position in your DMA, right? There's some markets where one hospital system just dominates and they tend to just do whatever they want and try to dictate to the insurance companies, you know, fees and rates and everything. And they haven't been as open to us because they don't want to see their contracts published, not because they don't want to do direct contracting, because direct contracting's not new, right? It's been around for a long time, but they don't want to see it published. So we'll go work with somebody who's not market dominant. And anybody who's not market dominant within a DMA loves us, right? Because we're a new source of patients. And physicians love us. You know, MRI, X-ray, any service operator, right, loves us. Clinics love us because, you know, their hope is by having that contract published, then they'll get a new flow of patients because the only reason they give lip service to the BUAs is because it's a flow of patients. You know, they control — you know, across all of them, there's 300 million insureds, right, that they control. That's — Amazon has 162 million customers, so that's almost twice as many, you know, that go through the BUAs. And so the opportunity to get away from that and be leaner and meaner and not so much mishagos, to use our favorite word, right, is attractive to them. And so we've gotten really positive responses and we've been out negotiating contracts for about a year. Like I said, we're past 9,000 providers and that number just continues to grow and we haven't even published anything yet.
Got it. And if you're an upstart payer like you are now, did you go with them at 100% Medicare? Like, how did you structure a contract?
We negotiated, right? Because we said, 'Here's your cash price. We get to see it in most cases. And why would we pay more than your cash price?' Because I can just give a credit card. But it's the more complicated things you have to negotiate, right? What if something goes wrong? What if there's an extended stay, you know, in the hospital, da da da da da? That's where the complications come in and that's where there's a negotiation. But like you already see insurers after X number of days trying to get you to push them to some external, you know, site to get them out of the hospital where it's cheaper, you know, we'll have that opportunity as well. But I'm hoping that because we negotiate at a cash price and we pay right up front, they'll keep those costs lower and we won't have to drag people around. The crazy — I mean, I don't know if you saw this, there's a story in The Washington Post about this doctor who had a fracture, ankle fracture after a car accident, was taken to a hospital and she had urgent surgery to set the fracture. And she got there in the evening, stayed overnight, and the insurance denied her hospital stay and gave her this massive bill because apparently she should have been sent home the same day alone on narcotics. It was like a $64,000 bill for something ridiculous. That's what — you know why they do that? Because they can. Because the hospitals expect to negotiate after the fact. And what — and I didn't read the whole article, I just saw the summary of it, and I think she negotiated it down after the fact, right? Because all this time, right, and effort and like whatever, right. Right, but that hospitals expect to do it, which is crazy in and of itself. Right, you shouldn't, you know, because that's an arbitrage on patient knowledge. Hospitals should not arbitrage patient awareness of their ability to negotiate. There's such an information asymmetry that that's not fair, right? Your trust score is going to go down when you do that. You know, and hospitals game the system with 340B, the site neutrality or lack thereof, facilities fees. So they're not — they're complicit in this at some level, but the starting point is that insurance plan that triggers everything. And so to change all this, that's where we have to start.
Yeah. I want to get back to Cost Plus for a second before we circle to PBMs, which I know is one of your favorite topics. One thing I found fascinating is as part of the Cost Plus journey, you got into manufacturing of drugs, right? And can you talk me through the complexity of setting up your own onshore US manufacturing?
The good news is that's where Alex shines, right? That's his baby. I deal with the front-facing stuff and the strategic stuff. But Alex, you know, is an AI savant in a lot of respects. So, you know, we used robotics and it took a couple years and a lot of money, but it's a robotics-driven factory that's geared towards sterile injectables. And we've learned a lot in the year and a half since we've launched. So hospitals, as you know, sterile water goes on short supply. You know, Pitocin goes on short supply. There's pediatric cancer drugs that go on short supply. And so we can manufacture all those things and sell it for less than, you know, what it costs when it doesn't go on short supply. And so that's been a good business for us.
But what it's really taught us is how we can modularize all of that. So that, you know, traditionally when you're looking to grow a factory that manufactures injectables or small molecule, whatever it may be, you just make a bigger factory to get your scale.
In our particular case, what Alex has been able to do is modularize it into pods. So, we've got these huge trailers that we're using to expand our capacity that not only can continue to do injectables if we reach capacity in the manufacturing plant, but we can do small molecules, but we can also do biologics. Not quite yet today, but very soon. And so, for biosimilars, we'll be able to manufacture those. And by the way, we're coming out with biosimilars. We already have them for ustekinumab and we'll have one for Stelara that will ship next week that's going to be like — I can't give you the price till next week, but it's going to be a lot lower than you expect. Let's put it that way. It'll be market-changing.
But to back to your point, so we're creating these pods. You know, they'll be $15 to $20 million depending on the configuration. But the ultimate application will be in a research hospital that does N-of-one biologics, cell and gene therapies, those types of things where they're doing research trying to save some child's life or person's life. And right now when you think you have a solution, you have to send it to a certain type of facility that might take weeks and cost at least a half a million dollars.
Well, by having this pod out in the parking lot, you'll be able to do it right there and it'll cost you $50,000 to $100,000 and take days so that you can reiterate. You can say, 'Okay, we're going to try this on your baby. You know, here's what we think is the right cell and gene response.' I'm not using the right terminology obviously, and if it doesn't work, then we're going to try this. We're going to iterate and try a different approach.